Abstract Number: 2224 • 2013 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Induces Anti-Citrullinated Protein Antibodies and Arthritis In Part Through Peptidyl Arginine Deiminase 4
Background/Purpose: Rheumatoid arthritis is an autoimmune, destructive arthritis characterized by anti-citrullinated protein antibodies (ACPAs) and high levels of inflammatory cytokines like tumor necrosis factor alpha…Abstract Number: 1314 • 2013 ACR/ARHP Annual Meeting
Synovial Ectopic Lymphoneogenesis Predicts Clinical Response To Certolizumab Pegol In Patients With Rheumatoid Arthritis
Background/Purpose: Predicting response to anti-TNF alpha inhibitors (TNFi) in rheumatoid arthritis (RA) patients is challenging. Therefore there is a high need for identification of biomarkers…Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…Abstract Number: 2401 • 2013 ACR/ARHP Annual Meeting
Disease Activity (DAS-28CRP) In Rheumatoid Arthritis Correlates With Synovial Expression Of Tumor-Associated and IL-6-Dependent Genes
Background/Purpose: The molecular mechanisms that regulate disease activity in rheumatoid arthritis (RA) are unknown. Using high-throughput transcriptomic data sets generated in knee synovial biopsies from…Abstract Number: 2127 • 2013 ACR/ARHP Annual Meeting
Recurrences Of Hallux Valgus Deformity After Implant Surgery For Greater Toe In Rheumatoid Arthritis
Background/Purpose: In advanced cases of rheumatoid arthritis (RA), Swanson implant have been widely usedfor hallux valgus deformity. Although the results for this surgery were acceptable,…Abstract Number: 1295 • 2013 ACR/ARHP Annual Meeting
Mechanisms For Fostamatinib-Induced Blood Pressure Elevation
Background/Purpose: Fostamatinib is a kinase inhibitor with activity at spleen tyrosine kinase. In clinical studies in patients with rheumatoid arthritis, fostamatinib treatment was associated with…Abstract Number: 455 • 2013 ACR/ARHP Annual Meeting
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Background/Purpose: Fostamatinib (Fosta) is a novel spleen tyrosine kinase (SYK) inhibitor. The Phase II TASKi studies showed benefit in patients (pts) with active rheumatoid arthritis…Abstract Number: 2382 • 2013 ACR/ARHP Annual Meeting
B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab
Background/Purpose: Rituximab is a safe and effective treatment in rheumatoid arthritis (RA), however the current treatment regimen requires to wait for a clinical relapse before…Abstract Number: 1978 • 2013 ACR/ARHP Annual Meeting
The Effect Of Certolizumab On Lymphatic Volume and Flow In Rheumatoid Arthritis Patients With Acute Flare
Background/Purpose: Episodic flare occurs in rheumatoid arthritis (RA) but the mechanisms of this process are not well understood. Our prior reports on MRI analysis of…Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…Abstract Number: 456 • 2013 ACR/ARHP Annual Meeting
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 24-wk study (NCT01197755) compared Fosta vs placebo (PBO) on methotrexate (MTX) treatment in patients (pts) with…Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
- « Previous Page
- 1
- …
- 180
- 181
- 182
- 183
- 184
- …
- 188
- Next Page »